{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T10:25:04Z","timestamp":1789640704656,"version":"4.0.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T00:00:00Z","timestamp":1746662400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000646","name":"JSPS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000646","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"AMED","doi-asserted-by":"publisher","award":["JP23jm0210080"],"award-info":[{"award-number":["JP23jm0210080"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.esmoop.2025.105306","type":"journal-article","created":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T13:59:15Z","timestamp":1749563955000},"page":"105306","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Association of KRAS variants with survival and therapeutic outcomes in biliary tract cancers"],"prefix":"10.1016","volume":"10","author":[{"given":"K.","family":"Iida","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Matsui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Urabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Muramatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Matsuzaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.esmoop.2025.105306_bib1","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.celrep.2019.03.088","article-title":"Establishment of patient-derived organoids and drug screening for biliary tract carcinoma","volume":"27","author":"Saito","year":"2019","journal-title":"Cell Rep"},{"issue":"3","key":"10.1016\/j.esmoop.2025.105306_bib2","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.ccell.2022.02.001","article-title":"Hepatobiliary tumor organoids for personalized medicine: a multicenter view on establishment, limitations, and future directions","volume":"40","author":"van Tienderen","year":"2022","journal-title":"Cancer Cell"},{"issue":"10","key":"10.1016\/j.esmoop.2025.105306_bib3","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1093\/oncolo\/oyac150","article-title":"Temporal changes in cholangiocarcinoma incidence and mortality in the United States from 2001 to 2017","volume":"27","author":"Javle","year":"2022","journal-title":"Oncologist"},{"key":"10.1016\/j.esmoop.2025.105306_bib4","article-title":"New perspectives in biliary tract cancers","volume":"5","author":"Goetze","year":"2024","journal-title":"ESMO Gastrointest Oncol"},{"issue":"8","key":"10.1016\/j.esmoop.2025.105306_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103647","article-title":"Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with biliary tract cancer","volume":"9","author":"Chen","year":"2024","journal-title":"ESMO Open"},{"issue":"14","key":"10.1016\/j.esmoop.2025.105306_bib6","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105306_bib7","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1002\/jhbp.1219","article-title":"Randomized phase III study of gemcitabine, cisplatin plus S-1 versus gemcitabine, cisplatin for advanced biliary tract cancer (KHBO1401- MITSUBA)","volume":"30","author":"Ioka","year":"2023","journal-title":"J Hepatobiliary Pancreat Sci"},{"issue":"8","key":"10.1016\/j.esmoop.2025.105306_bib8","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200015","article-title":"Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer","volume":"1","author":"Oh","year":"2022","journal-title":"NEJM Evid"},{"issue":"10391","key":"10.1016\/j.esmoop.2025.105306_bib9","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","article-title":"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Kelley","year":"2023","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.esmoop.2025.105306_bib10","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/S2468-1253(24)00095-5","article-title":"Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study","volume":"9","author":"Oh","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.esmoop.2025.105306_bib11","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1056\/NEJMcibr2408099","article-title":"KRAS oncoprotein signaling in cancer","volume":"392","author":"Lito","year":"2025","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.esmoop.2025.105306_bib12","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1001\/jamasurg.2015.0313","article-title":"Association between specific mutations in KRAS codon 12 and colorectal liver metastasis","volume":"150","author":"Margonis","year":"2015","journal-title":"JAMA Surg"},{"issue":"32","key":"10.1016\/j.esmoop.2025.105306_bib13","doi-asserted-by":"crossref","first-page":"34014","DOI":"10.18632\/oncotarget.5607","article-title":"KRAS mutations affect prognosis of non-small-cell lung cancer patients treated with first-line platinum containing chemotherapy","volume":"6","author":"Marabese","year":"2015","journal-title":"Oncotarget"},{"issue":"7","key":"10.1016\/j.esmoop.2025.105306_bib14","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1038\/bjc.2017.37","article-title":"Specific mutations in KRAS codon 12 are associated with worse overall survival in patients with advanced and recurrent colorectal cancer","volume":"116","author":"Jones","year":"2017","journal-title":"Br J Cancer"},{"issue":"3","key":"10.1016\/j.esmoop.2025.105306_bib15","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/s41591-023-02240-8","article-title":"Codon-specific KRAS mutations predict survival benefit of trifluridine\/tipiracil in metastatic colorectal cancer","volume":"29","author":"van de Haar","year":"2023","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105306_bib16","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1001\/jamasurg.2021.5679","article-title":"Association of KRAS variant subtypes with survival and recurrence in patients with surgically treated intrahepatic cholangiocarcinoma","volume":"157","author":"Zhou","year":"2022","journal-title":"JAMA Surg"},{"key":"10.1016\/j.esmoop.2025.105306_bib17","article-title":"KRAS variants are associated with survival outcomes and genomic alterations in biliary tract cancers","volume":"8","author":"Gelfer","year":"2024","journal-title":"JCO Precis Oncol"},{"issue":"5","key":"10.1016\/j.esmoop.2025.105306_bib18","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.9840","article-title":"KRAS allelic variants in biliary tract cancers","volume":"7","author":"Moffat","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"11","key":"10.1016\/j.esmoop.2025.105306_bib19","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1158\/2159-8290.CD-22-0417","article-title":"C-CAT: the national datacenter for cancer genomic medicine in Japan","volume":"12","author":"Kohno","year":"2022","journal-title":"Cancer Discov"},{"issue":"5","key":"10.1016\/j.esmoop.2025.105306_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.101627","article-title":"Genomic characterization of thymic epithelial tumors in a real-world dataset","volume":"8","author":"Kurokawa","year":"2023","journal-title":"ESMO Open"},{"issue":"5","key":"10.1016\/j.esmoop.2025.105306_bib21","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1158\/2159-8290.CD-23-0902","article-title":"Pan-cancer comparative and integrative analyses of driver alterations using Japanese and international genomic databases","volume":"14","author":"Horie","year":"2024","journal-title":"Cancer Discov"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105306_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.104108","article-title":"Efficacy of pembrolizumab in microsatellite-stable, tumor mutational burden-high metastatic colorectal cancer: genomic signatures and clinical outcomes","volume":"10","author":"Yamaguchi","year":"2025","journal-title":"ESMO Open"},{"issue":"12","key":"10.1016\/j.esmoop.2025.105306_bib23","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1016\/j.humpath.2013.07.026","article-title":"The frequency of KRAS and BRAF mutations in intrahepatic cholangiocarcinomas and their correlation with clinical outcome","volume":"44","author":"Robertson","year":"2013","journal-title":"Hum Pathol"},{"issue":"11","key":"10.1016\/j.esmoop.2025.105306_bib24","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/j.trecan.2023.07.004","article-title":"Immune vulnerabilities of mutant KRAS in pancreatic cancer","volume":"9","author":"Cheng","year":"2023","journal-title":"Trends Cancer"},{"issue":"13","key":"10.1016\/j.esmoop.2025.105306_bib25","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1917239","article-title":"KRASG12C inhibition with sotorasib in advanced solid tumors","volume":"383","author":"Hong","year":"2020","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.esmoop.2025.105306_bib26","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1200\/JCO.21.02752","article-title":"First-in-human phase I\/IB dose-finding study of adagrasib (MRTX849) in patients with advanced KRAS(G12C) solid tumors (KRYSTAL-1)","volume":"40","author":"Ou","year":"2022","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1016\/j.esmoop.2025.105306_bib27","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1056\/NEJMc2210539","article-title":"Adagrasib in non-small-cell lung cancer","volume":"387","author":"Kotecha","year":"2022","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105306_bib28","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1056\/NEJMoa2212419","article-title":"Adagrasib with or without cetuximab in colorectal cancer with mutated KRAS G12C","volume":"388","author":"Yaeger","year":"2023","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.esmoop.2025.105306_bib29","doi-asserted-by":"crossref","first-page":"4097","DOI":"10.1200\/JCO.23.00434","article-title":"Adagrasib in advanced solid tumors harboring a KRAS(G12C) mutation","volume":"41","author":"Bekaii-Saab","year":"2023","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2025.105306_bib30","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1158\/1078-0432.CCR-23-2098","article-title":"A small molecule with big impact: MRTX1133 targets the KRASG12D mutation in pancreatic cancer","volume":"30","author":"Wei","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.esmoop.2025.105306_bib31","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1158\/2159-8290.CD-24-0027","article-title":"Translational and therapeutic evaluation of RAS-GTP inhibition by RMC-6236 in RAS-driven cancers","volume":"14","author":"Jiang","year":"2024","journal-title":"Cancer Discov"},{"issue":"3","key":"10.1016\/j.esmoop.2025.105306_bib32","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.jhep.2022.11.030","article-title":"Charting co-mutation patterns associated with actionable drivers in intrahepatic cholangiocarcinoma","volume":"78","author":"Kendre","year":"2023","journal-title":"J Hepatol"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702925011755?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702925011755?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T07:14:49Z","timestamp":1751872489000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702925011755"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":32,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S2059702925011755"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2025.105306","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association of KRAS variants with survival and therapeutic outcomes in biliary tract cancers","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2025.105306","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"105306"}}